Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Abeona Therapeutics Inc. has an average analyst rating of "Moderate Buy", with one hold and five buy recommendations among the six brokerages covering the stock.
• The company's stock price target has been set at an average of $19.50, with some analysts like HC Wainwright and Oppenheimer setting targets at $20.00.
• Recent insider transactions include CEO Vishwas Seshadri selling 25,000 shares for approximately $131,000, reducing his holding by 2.06%.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $19.50.

ABEO has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday. Weiss Ratings reiterated a "hold (c-)" rating on shares of Abeona Therapeutics in a research report on Wednesday, October 8th. Finally, Oppenheimer boosted their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th.

Insider Transactions at Abeona Therapeutics

In other news, CEO Vishwas Seshadri sold 25,000 shares of the business's stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total value of $131,000.00. Following the sale, the chief executive officer owned 1,190,067 shares of the company's stock, valued at approximately $6,235,951.08. The trade was a 2.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joseph Walter Vazzano sold 9,035 shares of the business's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the completion of the sale, the chief financial officer directly owned 453,631 shares in the company, valued at $2,445,071.09. This represents a 1.95% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,865 shares of company stock valued at $347,777. Corporate insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning lifted its position in shares of Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock valued at $81,000 after acquiring an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at $25,000. Legal & General Group Plc acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at $27,000. OMERS ADMINISTRATION Corp lifted its position in shares of Abeona Therapeutics by 11.0% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after acquiring an additional 7,155 shares during the last quarter. Finally, Riverwater Partners LLC acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at $62,000. Institutional investors and hedge funds own 80.56% of the company's stock.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $5.53 on Thursday. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The business has a 50 day moving average of $6.18 and a two-hundred day moving average of $5.94. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54. The company has a market cap of $283.57 million, a P/E ratio of 7.90 and a beta of 1.42.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $2.10. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $21.71 million. As a group, analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current year.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.